Plain-English translation of NCT07243483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to better understand how venetoclax works in patients with acute myeloid leukemia (AML) who are receiving it as a first-line treatment. By studying blood samples from about 100 patients, this study will measure how the medication moves through your body and how it affects your cancer cells. The goal is to help doctors understand whether dose adjustments might help some patients in the future.
Venetoclax is an effective treatment for AML, but researchers don't yet fully understand how the medication behaves differently in different patients. This study will help fill that knowledge gap so doctors can eventually personalize treatment and potentially improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will continue receiving your standard AML treatment (venetoclax and azacitidine) exactly as planned—this study does not change your medical care. Over the course of the study, you will have up to 21 additional blood draws (about 12 milliliters total per visit, similar to a routine lab test) to measure how the medication is working in your body. The study lasts about 12 months, and your participation involves minimal extra burden beyond these scheduled blood samples.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
France